GlassScriptPhysician profile
Jamie Rich
NPI 1316565674
$11,183.71
in general payments reported to CMS, 2019-2025
65 companies · $2,228 in 2025
The $2,228 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $2,729 · 2023: $2,242 · 2024: $3,734 · 2025: $2,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,224 · Consulting Fee: $800 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,224.01 |
| Consulting Fee | $800.00 |
| Education | $180.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,760.04 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $1,033.71 | 2021-2025 | |
| Daiichi Sankyo INC. | $929.55 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $857.54 | 2021-2025 | Erleada, Balversa, Akeega |
| Eisai INC. | $749.85 | 2021-2025 | |
| Incyte Corporation | $562.17 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Regeneron Healthcare Solutions, INC. | $554.79 | 2022-2025 | Libtayo |
| Exelixis INC. | $505.22 | 2022-2025 | Cabometyx |
| Amgen INC. | $328.06 | 2021-2023 | Vectibix |
| Merck Sharp & Dohme LLC | $318.93 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Genzyme Corporation | $267.53 | 2022-2025 | |
| Tersera Therapeutics LLC | $222.79 | 2023-2025 | Xermelo, Zoladex, Quzyttir |
| Abbvie INC. | $189.22 | 2022-2025 | |
| Pfizer INC. | $162.21 | 2022-2025 | |
| Taiho Oncology, INC. | $151.95 | 2023-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $148.24 | 2021-2022 | |
| Caris Mpi, INC. | $145.82 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $142.94 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Genentech USA, INC. | $140.02 | 2022-2025 | Polivy, Lunsumio, Phesgo |
| Beigene USA, INC. | $105.65 | 2022-2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $101.70 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Blueprint Medicines Corporation | $91.68 | 2021-2024 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $88.06 | 2023-2025 | |
| Stemline Therapeutics INC. | $84.85 | 2023 | Orserdu |
| Servier Pharmaceuticals LLC | $83.76 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $81.00 | 2024 | |
| Pharmaessentia USA Corporation | $80.33 | 2023-2024 | Besremi |
| Sobi, INC | $79.98 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $77.07 | 2022-2025 | Monoferric, Cosela |
| Adc Therapeutics America, INC. | $69.58 | 2022-2025 | |
| Genmab U.S., INC. | $64.38 | 2023-2025 | Epkinly |
| Immunocore Limited | $63.05 | 2024-2025 | Kimmtrak |
| Deciphera Pharmaceuticals INC. | $61.58 | 2022-2025 | Qinlock, Romvimza |
| Sumitomo Pharma America, INC. | $61.18 | 2024 | Orgovyx |
| Emd Serono, INC. | $60.38 | 2022-2025 | |
| Lilly USA, LLC | $59.09 | 2021-2023 | Retevmo, Verzenio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.86 | 2024-2025 | |
| Beone Medicines USA, INC. | $45.38 | 2025 | Tevimbra, Brukinsa |
| Karyopharm Therapeutics INC. | $40.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.87 | 2022-2024 | Alunbrig |
| Alexion Pharmaceuticals, INC. | $37.12 | 2023-2024 | Ultomiris |
| Cumberland Pharmaceuticals, INC. | $34.49 | 2025 | Sancuso |
| Rigel Pharmaceuticals, INC. | $32.40 | 2022 | |
| Mirati Therapeutics, INC. | $31.46 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $30.14 | 2022-2023 | Fotivda |
| Apellis Pharmaceuticals, INC. | $28.97 | 2023-2024 | Empaveli |
| Seagen INC. | $28.70 | 2022-2023 | Padcev |
| Dendreon Pharmaceuticals LLC | $28.47 | 2024 | Provenge |
| Myovant Sciences INC. | $24.69 | 2022 | |
| Novocure INC. | $24.06 | 2025 | Optune Lua (Novottf-200t) |
| Ipsen Biopharmaceuticals, INC | $19.44 | 2025 | Onivyde |
| Astellas Pharma US INC | $17.27 | 2024 | Xospata |
| Kite Pharma, INC. | $17.06 | 2025 | Yescarta |
| Immunogen, INC. | $16.10 | 2023 | Elahere |
| Morphosys, US INC. | $15.42 | 2023 | Monjuvi |
| Novo Nordisk INC | $15.23 | 2025 | |
| Puma Biotechnology, INC. | $14.72 | 2023 | |
| Myriad Genetic Laboratories, INC. | $14.42 | 2025 | Myrisk |
| Agios Pharmaceuticals, INC. | $14.30 | 2025 | Pyrukynd |
| Acrotech Biopharma INC. | $13.66 | 2024 | Beleodaq |
| Spectrum Pharmaceuticals INC. | $13.20 | 2024 | Rolvedon |
| Veracyte, INC. | $12.24 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $11.84 | 2022 | |
| Coherus Oncology, INC. | $11.80 | 2022 | |
| Pharmaand Gmbh | $7.60 | 2024 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.